iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $72.59, for a total value of $362,950.00. Following the transaction, the chief executive officer directly owned 2,337,500 shares in the company, valued at $169,679,125. The trade was a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
iRadimed Stock Up 1.1%
IRMD stock traded up $0.83 during trading on Tuesday, reaching $73.24. The company's stock had a trading volume of 34,778 shares, compared to its average volume of 45,924. iRadimed Corporation has a 1 year low of $46.86 and a 1 year high of $78.38. The company has a market capitalization of $931.61 million, a P/E ratio of 45.21 and a beta of 1.02. The company's fifty day moving average is $71.48 and its 200-day moving average is $61.30.
iRadimed Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 28th. Shareholders of record on Monday, August 18th were paid a $0.17 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $0.68 annualized dividend and a yield of 0.9%. iRadimed's dividend payout ratio (DPR) is presently 41.98%.
Institutional Investors Weigh In On iRadimed
Hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in iRadimed by 2.1% in the first quarter. Teacher Retirement System of Texas now owns 51,359 shares of the medical equipment provider's stock valued at $2,695,000 after purchasing an additional 1,072 shares during the period. Envestnet Asset Management Inc. raised its position in iRadimed by 20.3% during the first quarter. Envestnet Asset Management Inc. now owns 70,473 shares of the medical equipment provider's stock worth $3,698,000 after acquiring an additional 11,892 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of iRadimed by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 101,665 shares of the medical equipment provider's stock valued at $5,335,000 after buying an additional 1,557 shares during the last quarter. Vanguard Group Inc. raised its position in shares of iRadimed by 3.3% in the first quarter. Vanguard Group Inc. now owns 554,451 shares of the medical equipment provider's stock valued at $29,098,000 after buying an additional 17,640 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in iRadimed in the first quarter valued at approximately $1,418,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a "buy (b-)" rating on shares of iRadimed in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $72.00.
View Our Latest Stock Analysis on iRadimed
iRadimed Company Profile
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.